Intelligence Feed event · Policy · 2026-08-27

    FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma

    Question

    FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma

    Direct answer

    The US Food and Drug Administration granted regulatory approval for Revolution Medicines' RASONQUE (daraxonrasib), marking the first targeted broad RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma patients who previously received chemotherapy. The approval stems from positive outcome data in the pivotal Phase 3 RASolute 302 clinical study. Revolution Medicines selected specialty pharmacy provider Onco360 to support the commercial drug launch and national fulfillment.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-adenocarcin-5d6a1c

    POLICY
    FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma
    The US Food and Drug Administration granted regulatory approval for Revolution Medicines' RASONQUE (daraxonrasib), marking the first targeted broad RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma patients who previously received chemotherapy. The approval stems from positive outcome data in the pivotal Phase 3 RASolute 302 clinical study. Revolution Medicines selected specialty pharmacy provider Onco360 to support the commercial drug launch and national fulfillment.
    RVMDIMRX
    Impact
    74
    AUG 27
    SIG
    90%
    RVMDIMRX
    FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma
    The US Food and Drug Administration granted regulatory approval for Revolution Medicines' RASONQUE (daraxonrasib), marking the first targeted broad RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma patients who previously received chemotherapy. The approval stems from positive outcome data in the pivotal Phase 3 RASolute 302 clinical study. Revolution Medicines selected specialty pharmacy provider Onco360 to support the commercial drug launch and national fulfillment.
    → FDA approval transitions Revolution Medicines into commercial-stage oncology sales, generating immediate specialty pharmacy prescription revenues.
    Impact
    The US Food and Drug Administration granted regulatory approval for Revolution Medicines' RASONQUE (daraxonrasib), marking the first targeted broad RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma patients who previously received chemotherapy. The approval stems from positive outcome data in the pivotal Phase 3 RASolute 302 clinical study. Revolution Medicines selected specialty pharmacy provider Onco360 to support the commercial drug launch and national fulfillment.
    Affected
    RVMDIMRX
    Transmission
    FDA approval transitions Revolution Medicines into commercial-stage oncology sales, generating immediate specialty pharmacy prescription revenues.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDcommercial drug authorization unlocking first-line and second-line oncology market revenueUp1-5dFDA approved RASONQUE for metastatic pancreatic cancer following Phase 3 trial.
    IMRXcompetitive re-evaluation in pancreatic cancer drug development pipelineMixed1-4wImmuneering reaffirmed focus on first-line pancreatic cancer following FDA approval of RASONQUE.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month